TP53 and colorectal carcinoma: While human colorectal carcinomas harbor frequent mutations of APC, TP53, PIK3CA and KRAS[31], our findings suggest that the TP53 mutations are associated with the resistance of colorectal carcinoma to the IGF-1R inhibitor, PPP.